VJHemOnc Podcast

MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF

The treatment of the BCR-ABL1-negative myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), has transformed in recent years. Several clinical trials are exploring the safety and efficacy of novel agents and combinations, with promising advances being made.

At the 65th ASH Annual Meeting and Exposition, leading experts Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, and Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, shared their key highlights in MPNs, commenting on ongoing trials and promising combinations being explored, as well as future outlooks.

iwNHL 2023 Session V: Expanding the CAR platform in NHL

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, and David Miklos, MD, PhD, Stanford University, Stanford, CA, discuss the growing role of CAR-T therapy in NHL and further comment on how to expand the CAR platform in this disease setting.

iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials

The biennial International Workshop on Chronic Lymphocytic Leukemia^TM (iwCLL 2023) was held recently in Boston, MA, and brought together experts who shared the latest updates in the treatment and management of CLL.

Tune in as we share some key highlights from this year's meeting. In this podcast, a variety of topics are covered, including the role of continuous BTK inhibitors (BTKis) in CLL, the importance of investigating the biology of Richter's transformation (RT), and the need to address the underrepresentation of elderly patients in CLL clinical trials. You will hear from several leading experts, including Kerry Rogers, MD, Ohio State University, Columbus, OH, Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd, CLL Society, Inc., Chula Vista, CA, Raul Cordoba, MD, PhD, University Hospital Fundación Jiménez Díaz, Madrid, Spain, and Adam Kittai, MD, Ohio State University, Columbus, OH.

iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Tanya Siddiqi, MD, City of Hope, Duarte, CA, and Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discuss the role of BTK inhibitors and degraders in NHL. Following this, you will hear from Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, Marion Subklewe, MD, Ludwig-Maximilians University, Munich, Germany, Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, and Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, who discuss the growing role of bispecific antibodies, including glofitamab, epcoritamab and odronextamab, in this disease setting.

Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP

In recent years, there have been promising therapeutic advances in light chain (AL) amyloidosis, however, several unmet needs remain in this disease. Early and accurate diagnosis present a key challenge, and both clinicians and researchers are investigating novel strategies with the aim of improving outcomes for patients. 

In this podcast, Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN, Paolo Lopedote, MD, St Elizabeth’s Medical Center, Boston, MA, Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Efstathios Kastritis, MD, University of Athens, Athens, Greece, discuss unmet needs in AL amyloidosis, as well as novel immunotherapy strategies being explored. The experts also highlight the prevalence of clonal hematopoiesis of indeterminate potential (CHIP) in this disease setting.

iwNHL 2023 Session III: Recent updates with the use of antibody-drug conjugates in NHL

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, John Gribben, MD, DSc, FRCPath, FRCP, FMedSci, Barts Cancer Institute, London, UK, Laurie Sehn, MD, University of British Columbia, Vancouver, Canada, Andrew Davies, MRCP, PhD, University of Southampton, Southampton, UK, and Sven De Vos, MD, PhD, David Geffen School of Medicine at UCLA, Los Angeles, CA, discuss novel therapies in NHL, drawing focus on the role of antibody-drug conjugates (ADCs).

MPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approaches

The treatment and management of myeloproliferative neoplasms (MPNs) including myelofibrosis (MF) and polycythemia vera (PV) has transformed in recent years, although several challenges remain. There are ongoing clinical trials investigating the safety and efficacy of novel agents for this group of diseases, as well as strategies to improve the diagnosis and risk stratification of patients.

In this podcast, Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Anthony Hunter, MD, Winship Cancer Institute of Emory University, Atlanta, GA, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, and John Mascarenhas, MD, Mount Sinai Medical Center, New York, NY, discuss several updates in the field of MPNs. Topics covered include novel agents being explored in PV, clinical guidance for the use of JAK inhibitors in MF, and the growing role of combination approaches.

iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, Marek Trněný, MD, PhD, Charles University, Prague, Czech Republic, John Kuruvilla, MD, Princess Margaret Cancer Centre, Toronto, Canada, and Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, share some insights into the evolving treatment landscape in mantle cell lymphoma (MCL), commenting on the changing role of transplantation and the impact of novel agents.

iwNHL 2023 Session I: Updates on the biology and treatment of T-cell lymphoma

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.

 

In this podcast, Francine Foss, MD, Yale School of Medicine, New Haven, CT, Laurence de Leval, MD, PhD, Lausanne University Hospital, Lausanne, Switzerland, Francois Lemonnier, MD, PhD, Henri Mondor University Hospital, Créteil, France, and Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discuss recent updates in the biology and treatment of T-cell lymphoma.

iwAL 2023 Session IV: transplantation and immunotherapies in AML: improving patient outcomes

The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, and Nelli Bejanyan, MD, Moffitt Cancer Center, Tampa, FL, discuss the most recent updates in transplantation and immunotherapies in AML, and further comment on how to improve outcomes for patients.